BioTelemetry (NASDAQ:BEAT) Upgraded to Sell by BidaskClub

BidaskClub upgraded shares of BioTelemetry (NASDAQ:BEAT) from a strong sell rating to a sell rating in a research report sent to investors on Thursday, BidAskClub reports.

Other equities analysts have also recently issued reports about the company. ValuEngine cut BioTelemetry from a hold rating to a sell rating in a report on Thursday, July 18th. Zacks Investment Research cut BioTelemetry from a buy rating to a hold rating in a report on Friday, August 2nd. TheStreet cut BioTelemetry from a b- rating to a c+ rating in a report on Friday, August 16th. Raymond James cut BioTelemetry from an outperform rating to a market perform rating in a report on Friday, August 2nd. Finally, Lake Street Capital set a $90.00 target price on BioTelemetry and gave the company a buy rating in a report on Wednesday, July 31st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $73.50.

BioTelemetry stock traded up $0.91 during midday trading on Thursday, reaching $42.98. 336,332 shares of the stock traded hands, compared to its average volume of 511,840. The company has a 50-day simple moving average of $41.62 and a two-hundred day simple moving average of $51.94. BioTelemetry has a 12-month low of $38.45 and a 12-month high of $80.92. The firm has a market cap of $1.37 billion, a PE ratio of 22.15, a price-to-earnings-growth ratio of 2.04 and a beta of 1.40. The company has a current ratio of 2.19, a quick ratio of 2.09 and a debt-to-equity ratio of 0.54.



BioTelemetry (NASDAQ:BEAT) last announced its earnings results on Tuesday, July 30th. The medical research company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.08. BioTelemetry had a return on equity of 22.98% and a net margin of 11.06%. The company had revenue of $111.80 million during the quarter, compared to analysts’ expectations of $111.11 million. During the same period last year, the business posted $0.46 EPS. BioTelemetry’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities research analysts anticipate that BioTelemetry will post 1.98 earnings per share for the current year.

In other news, SVP Peter Ferola sold 44,276 shares of BioTelemetry stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $39.03, for a total value of $1,728,092.28. Following the completion of the transaction, the senior vice president now owns 19,622 shares in the company, valued at approximately $765,846.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.50% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Chatham Capital Group Inc. lifted its stake in BioTelemetry by 0.7% during the first quarter. Chatham Capital Group Inc. now owns 32,397 shares of the medical research company’s stock worth $2,029,000 after purchasing an additional 214 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in BioTelemetry by 1.8% during the first quarter. Oregon Public Employees Retirement Fund now owns 12,898 shares of the medical research company’s stock worth $808,000 after purchasing an additional 233 shares during the last quarter. Mark Sheptoff Financial Planning LLC lifted its stake in BioTelemetry by 25.0% during the first quarter. Mark Sheptoff Financial Planning LLC now owns 1,500 shares of the medical research company’s stock worth $94,000 after purchasing an additional 300 shares during the last quarter. HMS Capital Management LLC lifted its stake in BioTelemetry by 3.8% during the second quarter. HMS Capital Management LLC now owns 8,205 shares of the medical research company’s stock worth $395,000 after purchasing an additional 300 shares during the last quarter. Finally, Flinton Capital Management LLC lifted its stake in BioTelemetry by 13.1% during the second quarter. Flinton Capital Management LLC now owns 3,584 shares of the medical research company’s stock worth $173,000 after purchasing an additional 416 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About BioTelemetry

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Recommended Story: Stochastic Momentum Index (SMI)

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.